本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
MIAMI, May 20, 2025 /PRNewswire/ -- Enfinity Global Inc., a leader in renewable energy, today announced the successful closing of an up to €100 million bond facility to support the deployment of its energy storage and solar PV projects across Europe. The facility is being provided by Eiffel Investment Group, an independent asset manager focused on sustainable investments, through four of its investment vehicles. This transaction marks a significant milestone, that underscores the platform's quality for investors and Enfinity's execution capabilities. It is also the company's first financing of its battery energy storage system (BESS) portfolio in Europe, where it is developing a 6.4 GW BESS pipeline—including 5.1 GW in Italy and 1.3 GW in the UK. Energy storage is a key component of Enfinity's strategy to deliver 24/7 renewable energy solutions to corporate and industrial customers while contributing to grid resilience. "We are thankful to Eiffel Investment Group for supporting the growth of our Italian platform," said Carlos Domenech, CEO of Enfinity Global. "The future of competitive low carbon energy solutions relies on innovation of technologies and financings supported by market leaders," he added. " We are proud to support Enfinity Global in its growth ," said Pierre-Antoine Machelon, head of Infrastructure Funds at Eiffel Investment Group . "Building a long-term relationship while structuring a tailor-made financing is at the heart of Eiffel DNA. This transaction highlights our commitment to providing financial solutions to accelerate the decarbonization in Europe ." Enfinity Global's has currently secured €865 million for Europe through multiple junior and senior debt agreements. The Company ranks among Italy's top 10 independent power producers (IPP) by installed capacity, with 232 MW operational, 538 MW under construction, and 805 MW of approved solar capacity. Enfinity also leads Italy's solar PPA market, having signed one-third of all the new capacity contracted in 2024[1]. "Enfinity Global continues to expand its renewable energy footprint, leveraging our expertise to accelerate the clean energy transition while delivering reliable and cost-effective solutions for the European market," commented Julio Fournier Fisas, General Manager of Enfinity Global for Europe. "We appreciate partners like Eiffel Investment Group who share our vision for the future of energy." "We are very happy to accompany top performing companies like Enfinity ," commented Jean-Charles Arrago, head of Eiffel Infrastructure debt strategy. "With this facility, we are able to accelerate the rollout of a 24/7 renewable electricity production capacity in Italy." [1] Elemens Dev & Deals 2024 Report and Elemens Lookout Q1 2025.
Largest Series A financing round in Asia's diagnostic technology sector since 2019 underscores strong investor confidence in PHASE Scientific's breakthrough diagnostic technology and growth vision. Investment to accelerate R&D and commercialization of cutting-edge early disease detection technology for multiple cancers, women's health issues, and infectious diseases. HONG KONG, May 20, 2025 /PRNewswire/ -- PHASE Scientific International Limited ("PHASE Scientific"), a pioneering biotechnology company revolutionizing early disease detection through proprietary urine-based diagnostics, today announced the successful completion of a US$34 million Series A funding round. This represents the largest Series A raise in Asia's diagnostic technology sector since 2019, reflecting robust investor conviction in PHASE Scientific's innovative PHASIFY™ technology and ambitious growth strategy. The funding round is led by a private equity fund managed by Value Partners Group (HKEX: 0806), one of Asia's largest independent asset management firms, with significant backing from new healthcare-focused investors and continued support from existing global backers. Building on its patented PHASIFY™ urine concentration technology—which captures over ten times more biomarkers than current industry gold standards—PHASE Scientific is the only player advancing a pipeline of urine-based liquid biopsy diagnostics. The company is developing a comprehensive suite of non-invasive tests for early detection of cancers, women's health conditions, and infectious diseases. Unlike traditional invasive screening methods, PHASIFY™ enables convenient, at-home sample collection, empowering proactive health management and preventive care. PHASE Scientific has demonstrated strong market traction with the successful launch and commercialization of over 30 innovative diagnostic products across multiple health categories, including respiratory, gastrointestinal, women's, sexual, pediatric health, and oncology. To date, the company has distributed more than 100 million tests in over 30 countries and conducted over 8 million laboratory tests worldwide. Building on this commercial success, PHASE Scientific has developed the world's first urine-based HPV test—a major breakthrough that has achieved significant clinical validation and global recognition. In a recent clinical study with Peking University Shenzhen Hospital, the test demonstrated 93.4% sensitivity in detecting CIN2+ lesions—including cervical precancer and cancer—and over 97% concordance with gold-standard physician-collected testing (Roche's Cobas 4800) for HPV types 16 and 18. The innovation earned the Thomas V. Sedlacek, MD, Prize for Best Clinical Research Abstract at the 2025 American Society for Colposcopy and Cervical Pathology (ASCCP) Annual Scientific Meeting and was featured at the Chinese Society for Colposcopy and Cervical Pathology (CSCCP) Conference, reflecting growing international interest and recognition. These results underscore PHASiFY™'s potential to make cervical cancer screening more accessible, comfortable, and user-friendly. "The successful close of this landmark Series A financing validates the transformative potential of our technology and the growing global demand for accessible, accurate early disease detection," said Dr. Ricky Chiu, Founder, Chairman and CEO of PHASE Scientific. "With this capital, we will accelerate R&D and commercialization efforts to bring a comprehensive suite of next-generation urine-based diagnostics to market. Our mission is to empower millions worldwide with non-invasive, user-friendly testing that can save lives through earlier intervention." "We are delighted to become a partner of PHASE Scientific as it rapidly grows and addresses critical unmet needs in early disease detection. Its innovative technology represents a paradigm shift, offering an unparalleled combination of clinical precision and patient-centric solutions that accelerates the development of early disease detection. This aligns with our strategy to back category-defining leader with strong management, clear strategic differentiation, and best-in-class healthcare technologies that deliver both societal impact and scalable commercial potential," said Dr. Chuen Yan Leung, Partner (Healthcare Investments) of Value Partners Group. Founded in 2015, the company is headquartered in Hong Kong SAR with cross-border setup in Southern California, U.S.A. and China's Greater Bay Area, which allows it to leverage the strengths of each region for research, development, and commercialization, positioning PHASE Scientific at the nexus for healthcare innovation on a global stage. Note to Editor: The global liquid biopsy market, fueled by the demand for non-invasive cancer diagnostics, is forecasted to reach around US$22.69 billion by 2034 at a CAGR of 13.91% from US$7.05 billion in 2025, according to Precedence Research. About PHASE Scientific PHASE Scientific is a fast-growing biotechnology company with a mission to inspire a new state of health through innovative diagnostics and healthcare solutions. With operations in the U.S., mainland China, and Hong Kong SAR, PHASE delivers novel diagnostic tools and services for cancer and infectious diseases using proprietary technologies, empowering better disease detection, diagnosis, and management. Since its founding, the company has been supported by Gates Foundation, US governmental agencies National Science Foundation and National Institute of Health, Ministry of Science and Technology of China, Hong Kong Innovation, Technology and Industry Bureau and Hong Kong Science and Technology Parks. For more information, please visit phasescientific.com. About PHASIFY™ PHASIFY™ is the world's first urine concentration technology designed for molecular diagnostics, setting a new industry benchmark by capturing approximately 10 times more target analytes from urine specimens compared to the current gold standard. This advanced mechanism enables the concentration and purification of unlimited volumes of urine, dramatically increasing the sensitivity and accuracy of disease detection. This proprietary innovation uniquely positions PHASE Scientific as the only player in the urine-based liquid biopsy diagnostics field, with proven clinical performance for multi-cancer detection. With a non-invasive and painless approach, PHASIFY™ empowers convenient sample collection, unlocking new possibilities for early, accessible, and comprehensive disease screening and diagnosis. About Value Partners Group Limited Value Partners, one of Asia's leading independent asset management firms, seeks to offer world-class investment services and products. Since its establishment in 1993, the Company has been a dedicated, specialist value investor in Greater China and Asia. In November 2007, Value Partners Group became the first asset management firm to be listed on the Main Board of the Hong Kong Stock Exchange (Stock code: 806 HK). In addition to its Hong Kong headquarters, the firm operates in Shanghai, Shenzhen, Singapore and London. Value Partners' investment strategies cover equities, fixed income, multi-asset, alternatives, real estate and quantitative investment solutions, for institutional and individual clients in Asia Pacific, Europe and the United States. For more information, please visit www.valuepartners-group.com. Media Contact PHASE Scientificpr@phasesci.com FGS GlobalPhaseSci@fgsglobal.com
The round was led by OM/VC (formerly Vectr Fintech) and MS&AD Ventures. New investors include Citi North America and Rustem Family office. Returning investors include 500 Global, Epic Angels, 1982 VC, and Big Sky Capital. CrediLinq operates in the embedded finance sector, enabling B2B platforms to offer financing solutions. Its AI-powered technology infrastructure integrates into online platforms through APIs and leverages the platform's real time alternative data to provide credit seamlessly to SMEs at the point of need. Funds will be deployed to drive market expansion, strategic acquisitions and partnerships in the US, UK and Australia; boost local presence in Singapore; hire senior commercial, product and tech talent and invest in further technology enhancements. SINGAPORE, May 16, 2025 /PRNewswire/ -- CrediLinq, the AI-powered embedded finance platform that is revolutionizing access to growth capital for underserved digital-first SMEs globally, announced today the close of its USD $8.5 million Series A funding round. The round was led by OM/VC and MS&AD Ventures. New investors include Citi North America and Rustem Family office. Returning investors include 500 Global, Epic Angels, 1982 VC and Big Sky Capital. CrediLinq will immediately accelerate geographic expansion, starting with the United States and subsequently into the United Kingdom and Australia. The company will look to partner with larger digital platforms in these markets to drive user growth, enabling digitally native businesses transacting on platforms to access capital. In addition, CrediLinq will strengthen its leadership bench in sales, marketing, product and tech to support expansion in the target markets. A significant portion of the funds will also be invested in enhancing the company's technology stack — with continual improvement of AI-led credit algorithms that use the SME's real-time digital footprint including platform data, unstructured data, bureau information and the like, to reduce non-performing loans (NPLs), improve 'Default On' collections, and build agentic workflows to drive efficiency. Deep Singh, Founder and Group CEO of CrediLinq, remarked: "Today marks a pivotal moment for CrediLinq as we accelerate the growth of embedded finance globally, helping platforms empower digital native SMEs with flexible, transparent and more seamless access to capital. With this new funding, we are excited to deepen our partnerships, expand into new markets, and invest in senior talent and technology infrastructure that will support the next phase of our growth." Vikram Kotibhaskar, Co-Founder of CrediLinq. added: "The embedded credit revolution continues to gain momentum, and CrediLinq is at the forefront of this innovation. By being integrated within platforms, our Credit-as-a-Service stack leverages API connectivity, transactional data and credit algorithms for quick decision-making at the point of need and offers easy checkout within the partner ecosystem. This results in a fast, frictionless and transparent customer experience and more ways for platforms to monetize their business. Our agentic workflows also drive efficiency and continuous monitoring to keep loan losses low. Platform partners benefit with higher stickiness, trust, and scalability that drives up GMV." CrediLinq Co-founders, Deep Singh (right) and Vikram Kotibhaskar (left) (Photo credit: CrediLinq) CrediLinq's solutions can be embedded across platforms that cover verticals of procurement, supply chain, e-commerce marketplaces, freelance platforms, banking, accounting, and payments. In the e-commerce space for example, CrediLinq has integrations with key marketplaces such as Amazon, Lazada and TikTok Shop. Mark Munoz, Managing Partner at OM/VC commented: "As a long-term investor in Credilinq, we're proud to support their growth into a global leader in credit-as-a-service. Their innovative use of technologies like AI to drive positive revenue outcomes for clients is aligned with our investment philosophy. It's also encouraging to see that many of its users have reported consistent, immediate ROI from their crediting platforms, underscoring the value that Credilinq is delivering at scale." Lee Smallwood, Global Head of Markets Innovation & Investments at Citi, said: "CrediLinq's innovative approach to embedded finance leverages AI to provide seamless credit solutions for digital-first SMEs, which complements our goal to transform financial services. Their platform's ability to integrate into diverse digital ecosystems positions them to make a significant impact globally." Jon Soberg, Managing Partner at MS&AD Ventures, mentioned: "CrediLinq's AI-driven platform offers a scalable solution to B2B platforms that want to embed lending as a complementary, value-add offering. Their focus on embedding credit within digital workflows is exactly what today's rapidly evolving digital economy demands." Vishal Harnal, Managing Partner at 500 Global, reflected: "We first backed CrediLinq in 2022 and are doubling down as they scale their AI-powered platform globally. Deep and his team bring exceptional domain expertise and execution, having already built a trusted, scalable model for embedded finance that allows them to expand beyond Southeast Asia." The CrediLinq team (Photo credit: CrediLinq) For more information about CrediLinq's embedded finance platform and Series A milestones, please visit www.credilinq.ai. About CrediLinq CrediLinq is a technology infrastructure company with a proprietary Credit-as-a-Service stack. Their API-centric approach enables B2B platforms and banks to build financial products for merchants, enabling the financial empowerment of underserved digital native SMEs to build, grow and scale their business. What sets CrediLinq apart is embedding lending solutions within these platforms and harnessing the platform's real-time alternative data, to offer business owners swift access to funding through AI-driven credit decisioning and agentic workflows. This empowers SMEs to manage cash flow by accessing seamless, flexible and transparent lending options. The company holds a Capital Markets Services License under the Monetary Authority of Singapore (MAS), enabling it to raise and deploy institutional capital to support SME growth. CrediLinq is ISO 27001 certified for information security management and is a member of the Singapore Fintech Association. About Citi Citigroup (NYSE: C), a leading global bank, invests in and partners with innovative startups that are transforming financial services and other industries. Focus areas include fintech, data analytics, and enterprise solutions. For more information, visit https://www.citi.com. About OM/VC OMVC is an early-stage venture capital firm targeting investment opportunities in fintech, deep tech, climate tech and where they intersect. With presence in San Francisco, Honolulu, New York and Singapore, it deploys private capital across Seed to Series A companies and provides visionary founders with operating expertise, capital formation advisory and access to talent. Founded by a former entrepreneur and a regulatory innovator, OMVC aims to create value on behalf of its investors, portfolio companies and the communities it operates in through integrating human-centric and tech-forward approaches. For more information, please visit: omvc.co. About MS&AD Ventures MS&AD Ventures is the corporate venture capital arm of MS&AD Insurance Group Holdings, one of the world's largest insurance groups. MS&AD Ventures invests in early-stage startups advancing innovation across insurtech, fintech, and ESG sectors. For more information, visit https://msad.vc/. About 500 Global 500 Global is a venture capital firm with US$2.2 billion in assets under management (as of 31 December 2024) investing in globally ambitious founders building fast-growing technology companies. The company focuses on the U.S. and global markets where innovation, capital, and ecosystems can propel startups and unlock long-term value. For more details, visit https://500.co/. Multimedia Links CrediLinq Company Overview CrediLinq LinkedIn Page [Founder Profiles: Deep Singh | Vikram Kotibhaskar]
Vitruvian Partners and WestCap Co-Lead Round with Support from 8VC, Valor Equity Partners and EDBI NEW YORK, May 13, 2025 /PRNewswire/ -- Addepar, a leading global technology and data platform that investment professionals rely on to make the most informed, data-driven investment decisions, announced today the closing of its $230 million Series G investment round. The round was co-led by Vitruvian Partners, headquartered in London, and returning investor, New York-based WestCap, with additional participation from longtime partners 8VC and Valor Equity Partners. Global investor EDBI, operating under SG Growth Capital—the investment platform of the Singapore Economic Development Board (EDB) and Enterprise Singapore—also joined this round as a new investor. Addepar's clients use its platform to manage and advise on more than $7 trillion in client assets, up from $5 trillion just a year ago. The company adds more than $25 billion in new assets on average each week, and serves more than 1,200 client firms across more than 50 countries. Addepar is the platform of choice for single-family offices, RIAs, large banks, institutional asset owners and alternative fund managers. With hundreds of thousands of users worldwide, Addepar has become a leader in wealth and investment management technology and data, and delivers outsized value specifically in times of market volatility. "This investment round reflects the deep trust our investors have in our mission, and the exceptional value we consistently deliver to our clients," said Eric Poirier, Chief Executive Officer at Addepar. "Since day one, our focus has been on building a unified platform that equips investment professionals with advanced technology, precise data, and actionable insights—essential tools for achieving extraordinary outcomes in today's rapidly evolving financial landscape. This funding aims to reward everyone who has contributed to our mission during our first 15 years, and reinforces our commitment to empowering the world's leading firms with deep and lasting innovation. It ensures that our clients are empowered with the right technology, data and tools to navigate the full range of market conditions with confidence." Addepar continues to invest over $100 million annually in research and development and is on track to achieve profitability in 2025. The proceeds from its Series G financing will primarily be used to provide liquidity to employees and other investors through a tender offer, allowing them to realize the value of their contributions. In addition, it will further accelerate investments in innovation and client capabilities, enabling firms to differentiate themselves in an increasingly competitive market. Addepar continues to deliver exceptional client satisfaction and retention, strong revenue growth, and rapid product innovation at scale. "Addepar has established itself as a category leader in investment technology with a strong track record of innovation and measurable global impact," said Luuk Remmen, Partner at Vitruvian Partners. "We're proud to bring more than capital to this partnership—offering strategic insight to help accelerate Addepar's next phase of global growth and extend its transformative solutions to more investment professionals worldwide." "We're proud to deepen our partnership with Addepar as they push the boundaries of innovation across the wealth management ecosystem, providing essential solutions for today's investment managers," said Jaime Hildreth, Partner at WestCap and Addepar board member. "We recognized Eric and the Addepar team's vision from the outset and will continue to work alongside their team to build, scale, and pioneer the future of investment management." Born in response to the 2008 global financial crisis, Addepar has maintained an unwavering focus on empowering investment professionals with the best data, technology and insights. In doing so, it has set a new standard for the world's leading wealth managers and investors. "Addepar is building the global operating system for investment professionals—connecting data, insight, and action in one powerful platform," said Joe Lonsdale, General Partner at 8VC and Addepar's Co-founder and Chairman of the Board. "This milestone reflects the market's belief in that vision and the strength of the team driving it. As Addepar expands its global reach, it's redefining how capital is managed and decisions are made across the investment ecosystem." Today, amid significant market turbulence and economic uncertainty, Addepar is uniquely positioned to double down on innovation—expanding its platform to help clients navigate volatility, manage risk, and deliver differentiated value to their own clients with greater speed, accuracy, and insight. As the company continues to grow, it remains deeply committed to driving meaningful, long-term impact across global markets by empowering firms to act with greater clarity and confidence. About AddeparAddepar is a global technology and data company that helps investment professionals provide the most informed, precise guidance for their clients. Hundreds of thousands of users have entrusted Addepar to empower smarter investment decisions and better advice over the last decade. With client presence in more than 50 countries, Addepar's platform aggregates portfolio, market and client data for more than $7 trillion in assets. Addepar's open platform integrates with more than 100 software, data and services partners to deliver a complete solution for a wide range of firms and use cases. Addepar embraces a global flexible workforce model with offices in Silicon Valley, New York City, Salt Lake City, Chicago, London, Edinburgh, Pune and Dubai. About Vitruvian PartnersVitruvian Partners is a global growth-focused investor with offices across London, Stockholm, Munich, Madrid, Luxembourg, Mumbai, Singapore, Shanghai, Miami, and San Francisco. Vitruvian focuses on dynamic situations characterized by rapid growth and change across asset-light industries. Vitruvian has over $20 billion of active funds which have backed many global winners and leaders in their sectors, including Wise, Marqeta, CFC, Global-e, Darktrace, Just Eat, and Skyscanner. Further information can be found at www.vitruvianpartners.com. About WestCap WestCap is a strategic operating and investing firm that partners with visionary leaders to build generational businesses. Our team is comprised of seasoned industry leaders and entrepreneurs who guide companies through the most pivotal stages of growth. Some of our notable investments include Airbnb, StubHub, Ipreo, Addepar, Hopper, iCapital, SIMON, and GoodLeap. The firm has offices in New York, San Francisco and London. For more information, please visit www.westcap.com.
SHENZHEN, China, May 9, 2025 /PRNewswire/ -- On May 6, 2025, Big Tree Cloud Investment Holdings Group (NASDAQ: DSY) (the "Group") successfully completed a new round of strategic capital increase with participation from Shenzhen Wengu Development Investment Partnership (Limited Partnership) ("Shenzhen Wengu"). The proceeds will be allocated to deepen supply chain integration, industrial consolidation, and R&D innovation in new materials within the personal care sector, further solidifying the Group's leadership as China's premier international capital platform in the personal care industry. According to the agreement, Shenzhen Wengu shall invest RMB 30 million into Guangdong Big Tree Cloud Investment Holding Group Co., Ltd. ("Guangdong Big Tree Cloud") in phases ("Wengu Investment"). The first three tranches totaling RMB 23 million were received in February, March, and April 2025, and the fourth tranche amounted of RMB 1 million will be received by May 31, 2025.The remaining RMB 6 million investment will be expected to be received in July 2025. Following a previous capital increase of US$ 600,000 (RMB4,314,060) from Hongkong Ploutos International Limited ("DSY HK") in December 2024 and Wengu Investment, the registered capital of Guangdong Big Tree Cloud was increased to RMB35,773,624. Of this amount, DSY HK held a 95.92% equity interest, while Shenzhen Wengu held the remaining 4.08%. Chairman Zhu Wenquan emphasized: "This capital increase validates our strategic roadmap and marks a milestone in capital structure optimization. The enhanced financial capacity will fuel future strategic execution and business expansion." Established in 2020 and listed on Nasdaq via De-SPAC transaction in 2024 as China's first personal care company on the U.S. exchange, Big Tree Cloud continues to reshape the industry landscape with post-IPO capital advantages and global vision. Moving forward, the Group will intensify M&A activities, collaborate with partners to create long-term value, and pursue high-quality growth in the personal care sector. Investor Relations ContactTing YanPhone: +86 15986815865Email: yanting@bigtreeclouds.com
FUKUOKA, Japan, May 8, 2025 /PRNewswire/ -- Medmain Inc., a Japanese medtech startup that offers PidPort, an AI-powered cloud system to assist in digital pathology, is pleased to announce that it has raised 3.3 million USD through a third-party allotment of shares, with One Capital as the lead investor and Niremia Collective and Plug and Play as additional participants. With this round, the company's total equity funding has reached 18 million USD. Medmain has rased 3.3M USD About Medmain Inc. Medmain Inc. is a Japanese medtech startup with the corporate mission "To create a world where medical services can be accessed with technology anywhere, anytime". As a partner to medical professionals around the world, the company develops and provides PidPort, an AI-powered cloud system that supports digital pathology. Learn more at: https://en.medmain.com Medmain has been providing a full range of services in the field of digital pathology, starting with a digitization service for specimen slides, to remote diagnosis support that connects remote facilities via cloud computing, to the presentation of high accuracy and rapid analysis of pathology results using AI, all of which are utilized at many facilities. We have also succeeded in accelerating the speed of development of pathology AI, our core technology, by creating a proprietary platform that accelerates AI development by means of transfer learning. About PidPort: https://us.medmain.com Purpose and Background of the Fundraising (Challenges Medmain Aims to Address) The funds raised will be used to further enhance the development of our product "PidPort," invest in infrastructure for digitalization, strengthen our sales organization, apply for regulatory approval of our pathology AI, and build a foundation for international expansion. With the global increase in cancer diagnoses, the number of pathology examinations has also risen significantly, leading to a chronic shortage of personnel and placing a heavy workload on medical institutions. Traditionally, pathology diagnoses have long relied on physical glass slides, but at Medmain, we have been supporting medical institutions through the provision of digital services and our platform, "PidPort." PidPort is currently used by many clients in a wide range of settings, including remote diagnostic support and consultations between medical institutions, multi-facility conferences, academic conferences, educational use in lectures and training sessions, as well as research and quality control at universities and corporations. Moving forward, we will continue to enhance functionality and strengthen integration with surrounding systems to further improve service convenience. At the same time, we are committed to expanding support and value delivery to more medical sites, and to strengthening our organizational structure in preparation for global expansion. [Comments from Investors] One Capital "Medmain is delivering and implementing an innovative solution that integrates digital pathology and AI in the highly specialized and experience-driven field of pathology diagnosis. We are deeply impressed by their AI diagnostic technology grounded in a strong understanding of pathology, the high level of product maturity, the exceptional breadth of cancer types covered—surpassing global competitors—their ability to embed solutions into clinical settings through co-creation with healthcare professionals, and the passion and execution capability of Mr. Iizuka and the team. We are confident that Medmain will play a vital role in dramatically advancing the quality, speed, and accessibility of medical care. We will fully support their business expansion across funding, talent, and strategic development." — Yukako Yokota, Partner, One Capital. [About One Capital] One Capital is an independent venture capital firm that invests in and supports SaaS and healthcare startups. They provide hands-on support from both a business and financial perspective, fully backing bold initiatives that create lasting value for society. They also operate a unique business model that includes offering DX advisory services and developing SaaS products for their limited partners. Niremia Collective "We at Niremia Collective are honored to participate in this funding round, strongly resonating with Medmain's vision and technological capabilities in addressing challenges within the field of pathology. Amid a global shortage of pathologists, Medmain's AI-powered digital pathology solution "PidPort" offers a profoundly impactful approach by simultaneously improving access to care and diagnostic accuracy. In particular, the platform's ability to handle multiple organ types with high precision and its strong implementation capability, grounded in collaboration with clinical settings, suggest tremendous potential for further expansion both in Japan and abroad. Guided by our mission to realize wellbeing through technology, we are committed to supporting initiatives that enhance the quality and sustainability of healthcare. We will continue to stand alongside Medmain as a strategic partner in creating global impact and driving growth." — Naoko Okumoto, Founder and Managing Partner, Niremia Collective. [About Niremia Collective] Niremia Collective is a venture capital firm based in Silicon Valley, USA, specializing in the wellbeing technology sector. It was founded by Naoko Okumoto, an expert in business development and investment across Silicon Valley and the Asia-Pacific region, and Nichol Bradford, the founder of Transformative Technology, the world's largest and most recognized ecosystem for wellbeing technology. Plug and Play "We at Plug and Play are thrilled to announce our investment in Medmain, a healthcare AI company transforming pathology through technology. With the strong support of numerous corporate partners and new government initiatives in Japan, we believe the country is emerging as a prime destination for global investors seeking the next generation of unicorns." — Alireza Masrour, General Partner, Plug and Play. [About Plug and Play] Plug and Play is a top-tier global venture capital firm and accelerator headquartered in Silicon Valley, USA. The company invests in and supports startups with innovative technologies and ideas. Plug and Play has a strong track record of nurturing unicorn companies such as PayPal, Dropbox, Guardant Health, and LendingClub. Representative Comment Medmain Inc.CEO Osamu Iizuka "We are honored to welcome such strong investors who highly value Medmain's mission, technological capabilities, and accomplishments in addressing critical healthcare challenges in the field of pathology through the power of technology. Our platform, "PidPort," is already being used in a wide range of clinical settings, contributing to improvements in the quality of care, operational efficiency, and research and development. Moving forward, we will further accelerate product development by enhancing integration with hospital and diagnostic systems, strengthening AI functionalities, and improving overall usability to deliver an even better service. Beyond Japan, we aim to expand globally and actively contribute to solving healthcare challenges around the world." Medmain Inc.
A12 藝術空間
Financing agreements
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
